N@N

Joseph Schwartz Reiterated (SRPT) at Buy and Held Target at $160 on, Jan 20th, 2023

Joseph Schwartz of SVB Leerink, Reiterated "Sarepta Therapeutics, Inc." (SRPT) at Buy and Held Target at $160 on, Jan 20th, 2023.

Joseph has made no other calls on SRPT in the last 4 months.

There are 8 other peers that have a rating on SRPT. Out of the 8 peers that are also analyzing SRPT, 2 agree with Joseph's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Judah Frommer of "Credit Suisse" Maintained at Hold with Increased Target to $114 on, Tuesday, January 10th, 2023
• Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $141 on, Thursday, October 13th, 2022

These are the ratings of the 6 analyists that currently disagree with Joseph

---

• Gil Blum of "Needham" Maintained at Strong Buy with Increased Target to $160 on, Tuesday, January 10th, 2023
• Yun Zhong of "BTIG" Maintained at Strong Buy with Increased Target to $160 on, Thursday, December 22nd, 2022
• Colin Bristow of "UBS" Upgraded from Hold to Strong Buy and Increased Target to $158 on, Friday, December 16th, 2022
• Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Increased Target to $138 on, Tuesday, November 29th, 2022
• Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $171 on, Thursday, November 3rd, 2022
• Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $190 on, Thursday, November 3rd, 2022

Contributing Sources

---